Ksanomelin (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ksanomelin" in Serbian language version.

refsWebsite

Global rank Serbian rank

9nih.gov

4^th place

8^th place

7doi.org

2^nd place

4^th place

2elsevier.com

610^th place

653^rd place

2psychiatryonline.org

4,032^nd place

2,550^th place

1cas.cz

2,066^th place

4,060^th place

1aspetjournals.org

6,663^rd place

3,586^th place

aspetjournals.org

jpet.aspetjournals.org

Grant MK, El-Fakahany EE (2005). „Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor”. The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 313—9. PMID 16002459. doi:10.1124/jpet.105.090134.

cas.cz

biomed.cas.cz

Jakubík J, Michal P, Machová E, Dolezal V (2008). „Importance and prospects for design of selective muscarinic agonists” (PDF). Physiological Research / Academia Scientiarum Bohemoslovaca. 57 Suppl 3: S39—47. PMID 18481916.

doi.org

Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA (2009). „Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice”. European Journal of Pharmacology. 603 (1-3): 147—9. PMID 19111716. doi:10.1016/j.ejphar.2008.12.020.
Heinrich JN; Butera JA; Carrick T; et al. (2009). „Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists”. European Journal of Pharmacology. 605 (1-3): 53—6. PMID 19168056. doi:10.1016/j.ejphar.2008.12.044.
Grant MK, El-Fakahany EE (2005). „Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor”. The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 313—9. PMID 16002459. doi:10.1124/jpet.105.090134.
Lieberman JA, Javitch JA, Moore H (2008). „Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry”. The American Journal of Psychiatry. 165 (8): 931—6. PMID 18676593. doi:10.1176/appi.ajp.2008.08050769.
Messer WS (2002). „The utility of muscarinic agonists in the treatment of Alzheimer's disease”. Journal of Molecular Neuroscience : MN. 19 (1-2): 187—93. PMID 12212779. doi:10.1007/s12031-002-0031-5.
Mirza NR, Peters D, Sparks RG (2003). „Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists”. CNS Drug Reviews. 9 (2): 159—86. PMID 12847557. doi:10.1111/j.1527-3458.2003.tb00247.x.
Shekhar A; Potter WZ; Lightfoot J; et al. (2008). „Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia”. The American Journal of Psychiatry. 165 (8): 1033—9. PMID 18593778. doi:10.1176/appi.ajp.2008.06091591.

elsevier.com

linkinghub.elsevier.com

Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA (2009). „Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice”. European Journal of Pharmacology. 603 (1-3): 147—9. PMID 19111716. doi:10.1016/j.ejphar.2008.12.020.
Heinrich JN; Butera JA; Carrick T; et al. (2009). „Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists”. European Journal of Pharmacology. 605 (1-3): 53—6. PMID 19168056. doi:10.1016/j.ejphar.2008.12.044.

nih.gov

ncbi.nlm.nih.gov

Farde L; Suhara T; Halldin C; et al. (1996). „PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man”. Dementia (Basel, Switzerland). 7 (4): 187—95. PMID 8835881.
Jakubík J, Michal P, Machová E, Dolezal V (2008). „Importance and prospects for design of selective muscarinic agonists” (PDF). Physiological Research / Academia Scientiarum Bohemoslovaca. 57 Suppl 3: S39—47. PMID 18481916.
Woolley ML, Carter HJ, Gartlon JE, Watson JM, Dawson LA (2009). „Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice”. European Journal of Pharmacology. 603 (1-3): 147—9. PMID 19111716. doi:10.1016/j.ejphar.2008.12.020.
Heinrich JN; Butera JA; Carrick T; et al. (2009). „Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists”. European Journal of Pharmacology. 605 (1-3): 53—6. PMID 19168056. doi:10.1016/j.ejphar.2008.12.044.
Grant MK, El-Fakahany EE (2005). „Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor”. The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 313—9. PMID 16002459. doi:10.1124/jpet.105.090134.
Lieberman JA, Javitch JA, Moore H (2008). „Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry”. The American Journal of Psychiatry. 165 (8): 931—6. PMID 18676593. doi:10.1176/appi.ajp.2008.08050769.
Messer WS (2002). „The utility of muscarinic agonists in the treatment of Alzheimer's disease”. Journal of Molecular Neuroscience : MN. 19 (1-2): 187—93. PMID 12212779. doi:10.1007/s12031-002-0031-5.
Mirza NR, Peters D, Sparks RG (2003). „Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists”. CNS Drug Reviews. 9 (2): 159—86. PMID 12847557. doi:10.1111/j.1527-3458.2003.tb00247.x.
Shekhar A; Potter WZ; Lightfoot J; et al. (2008). „Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia”. The American Journal of Psychiatry. 165 (8): 1033—9. PMID 18593778. doi:10.1176/appi.ajp.2008.06091591.

psychiatryonline.org

ajp.psychiatryonline.org

Lieberman JA, Javitch JA, Moore H (2008). „Cholinergic agonists as novel treatments for schizophrenia: the promise of rational drug development for psychiatry”. The American Journal of Psychiatry. 165 (8): 931—6. PMID 18676593. doi:10.1176/appi.ajp.2008.08050769.
Shekhar A; Potter WZ; Lightfoot J; et al. (2008). „Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia”. The American Journal of Psychiatry. 165 (8): 1033—9. PMID 18593778. doi:10.1176/appi.ajp.2008.06091591.